Proton Pump Inhibitors and Lymphocytic Esophagitis : A Novel Association?

Salima Haque, Robert M. Genta, Miraca Life Sciences Research Institute, Irving, TX

Lymphocytic esophagitis was first described by Rubio et al. as an entity in 2006; however, in 2008 Purdy et al. reviewed 42 cases of lymphocytic esophagitis and dismissed it as a non-specific response of uncertain relevance. We recently reviewed the histopathology and clinical correlations of 42 patients with dense lymphocytic infiltrates in the esophageal mucosa and concluded that lymphocytic esophagitis is a specific type of inflammatory disorder of the esophagus.

To read the rest of this article, please contact Miraca Life Sciences

Choose Miraca for Your Patients

Learn more about Miraca's Anatomic Pathology services

Learn More »
TRADESHOWS >> FIND posters and presentations from past shows, and see where Miraca Life Sciences will be next.

We’re pleased with the excellent MU resources that Steve Sharp has provided, and the advocacy he has taken on our behalf. Howard Gervasoni is a true MU SME, helping us to understand the rules and their applicability to us on a pragmatic basis, assisting [with] implementing the compliance mechanics within our practice’s clinical operations, guiding our scorekeeping analytics as we monitored our performance through the measurement periods, testing our IT systems and security as appropriate, and supporting our input submission and validation processes. In addition to technical competence, he has great interpersonal skills—important in helping irritated lay people deal with a perceived “nuisance” endeavor. The “bottom line” is that with Miraca’s help we achieved our MU goals which were of significant consequence to us!
— Morgan Hunnewell, Practice Manager; Ron Drabik, Project Administrator; Dr. Vinod Thakkar, President,
Thakkar, Patel & Avalos, Sebring, Fla.

Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.
Get news from Miraca. Join our email list.